SCHEMBL14320484

SCHEMBL14320484

O=C(O)c1ccc(Nc2nc(-c3ccccc3)nc3cn[nH]c23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.65
ABCC1 P33527 2/20 0.65
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
SIRT5 Q9NXA8 1/20 0.64
PDE4B Q07343 7/20 0.60
PDE4D Q08499 7/20 0.60
ABCB1 P08183 1/20 0.57
RXRA P19793 4/20 0.56
NR4A2 P43354 4/20 0.56
RORC P51449 1/20 0.53
MAPK14 Q16539 1/20 0.53
POLB P06746 1/20 0.52
CTDSP1 Q9GZU7 1/20 0.52
PDE5A O76074 1/20 0.51
SYK P43405 4/20 0.51
JAK2 O60674 2/20 0.51
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320764 0.91 KDM1A (0.54) ABCG2ABCC1MEN1KMT2ASIRT5
SCHEMBL14320769 0.82 SYK (0.64) SYKJAK2MAPT
SCHEMBL14321317 0.82 ABCG2 (0.66) ABCG2ABCC1MEN1KMT2APDE4B
SCHEMBL14320367 0.82 KDM1A (0.66) MEN1KMT2ASYKJAK2KDM4E
SCHEMBL14320361 0.82 ABCG2 (0.53) ABCG2ABCC1ABCB1SYK
SCHEMBL14320415 0.81 SYK (0.54) SYKJAK2
SCHEMBL13741113 0.81 MEN1 (0.55) ABCG2MEN1KMT2AABCB1PDE5A
SCHEMBL14320687 0.80 ABCG2 (0.43) ABCG2ABCC1MEN1KMT2ASIRT5
SCHEMBL14320502 0.80 FGFR1 (0.48) ABCG2MEN1KMT2ASYKJAK2
SCHEMBL14320626 0.80 ABCG2 (0.66) ABCG2MEN1KMT2AABCB1PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 CN claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
CN-103492389-B Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases 原真股份有限公司 2016-09-14 CN disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
CN-103492389-A Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors ORIGENIS GMBH 2014-01-01 CN disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK ABCG2 3810/4885ABCC1 4003/4885MEN1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.